🔎 Trials Near Me

Utama › Purpura Trombositopenik Idiopatik › Massachusetts

Kajian klinikal Purpura Trombositopenik Idiopatik di Massachusetts

6 kajian untuk Purpura Trombositopenik Idiopatik sedang mencari peserta di lokasi di Massachusetts.

Bandar di Massachusetts

Teks kajian rasmi (Bahasa Inggeris)

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06722235

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

  • Beth Israel Deaconess Medical Center, Boston
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07095127

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

  • Beth Israel Deaconess Medical Center, Boston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07104565

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
  • University of Massachusetts Chan Medical School, Worcester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06948318

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  • Massachusetts General Hospital Cancer Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Mass General Brigham Cancer Institute, Danvers
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT07007962

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Feb 2025 · NCT06817395

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.